SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. Mar 10 2005; 352( 10): 987-996.
  • 2
    Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. Mar 10 2005; 352( 10): 997-1003.
  • 3
    Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. Oct 23 2008; 455( 7216): 1061-1068.
  • 4
    Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. Sep 26 2008; 321( 5897): 1807-1812.
  • 5
    Yan H, Bigner DD, Velculescu V, Parsons DW. Mutant metabolic enzymes are at the origin of gliomas. Cancer Res. Dec 15 2009; 69(24): 9157-9159.
  • 6
    Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. Feb 19 2009; 360( 8): 765-773.
  • 7
    Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. Oct 1 2009; 15( 19): 6002-6007.
  • 8
    Kleihues P BP, Collins VP, et al, ed. WHO Classification of Tumours of the Central Nervous System. Lyon: WHO Press; 2000. IARC,ed.
  • 9
    Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. Aug 2007; 114( 2): 97-109.
  • 10
    Wakabayashi T, Hatano N, Kajita Y, et al. Initial and maintenance combination treatment with interferon-beta, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma. J Neurooncol. Aug 2000; 49( 1): 57-62.
  • 11
    Wakabayashi T, Kayama T, Nishikawa R, et al. A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study). Jpn J Clin Oncol. Oct 2008; 38( 10): 715-718.
  • 12
    Franco-Hernandez C, Martinez-Glez V, Alonso ME, et al. Gene dosage and mutational analyses of EGFR in oligodendrogliomas. Int J Oncol. Jan 2007; 30( 1): 209-215.
  • 13
    Jeuken J, Cornelissen S, Boots-Sprenger S, Gijsen S, Wesseling P. Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn. Sep 2006; 8( 4): 433-443.
  • 14
    Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. Jun 15 2002; 30( 12): e57.
  • 15
    Martinez-Glez V, Franco-Hernandez C, Lomas J, et al. Multiplex ligation-dependent probe amplification (MLPA) screening in meningioma. Cancer Genet Cytogenet. Mar 2007; 173( 2): 170-172.
  • 16
    Natsume A, Wakabayashi T, Tsujimura K, et al. The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer. Jun 1 2008; 122( 11): 2542-2553.
  • 17
    Oi S, Natsume A, Ito M, et al. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2′-deoxycytidine in glioma cells. J Neurooncol. Mar 2009; 92( 1): 15-22.
  • 18
    Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res. Feb 1 1992; 52( 3): 674-679.
  • 19
    Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. Oct 2009; 118( 4): 469-474.
  • 20
    Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. Oct 1 2004; 64( 19): 6892-6899.
  • 21
    Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. Dec 1 2009; 27( 34): 5743-5750.
  • 22
    Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. Sep 1 2008; 26( 25): 4189-4199.
  • 23
    Chinot OL, Barrie M, Fuentes S, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol. Apr 20 2007; 25( 12): 1470-1475.
  • 24
    Eoli M, Menghi F, Bruzzone MG, et al. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res. May 1 2007; 13( 9): 2606-2613.
  • 25
    Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. Nov 9 2000; 343( 19): 1350-1354.
  • 26
    Ruano Y, Ribalta T, de Lope AR, et al. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. Am J Clin Pathol. Feb 2009; 131( 2): 257-263.
  • 27
    Waldman YY, Tuller T, Sharan R, Ruppin E. TP53 cancerous mutations exhibit selection for translation efficiency. Cancer Res. Nov 15 2009; 69( 22): 8807-8813.
  • 28
    Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. Dec 2007; 6( 12): 975-990.
  • 29
    Natsume A, Ishii D, Wakabayashi T, et al. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. Sep 1 2005; 65( 17): 7573-7579.
  • 30
    Natsume A, Wakabayashi T, Ishii D, et al. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol. Apr 2008; 61( 4): 653-659.